2172 Stock Overview
MicroPort NeuroTech Limited engages in the research and development, production, and sale of neuro-interventional medical devices in the People’s Republic of China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 2172 from our risk checks.
MicroPort NeuroTech Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$9.31 |
| 52 Week High | HK$14.60 |
| 52 Week Low | HK$8.04 |
| Beta | 0 |
| 1 Month Change | 11.10% |
| 3 Month Change | 2.08% |
| 1 Year Change | -30.11% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -42.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2172 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | 11.8% | 8.0% | 5.5% |
| 1Y | -30.1% | -48.4% | -9.1% |
Return vs Industry: 2172 exceeded the Hong Kong Medical Equipment industry which returned -48.4% over the past year.
Return vs Market: 2172 underperformed the Hong Kong Market which returned -9.1% over the past year.
Price Volatility
| 2172 volatility | |
|---|---|
| 2172 Average Weekly Movement | 6.2% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 14.8% |
| 10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 2172 has not had significant price volatility in the past 3 months.
Volatility Over Time: 2172's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 571 | Zhiyong Xie | www.medneurotech.com |
MicroPort NeuroTech Limited engages in the research and development, production, and sale of neuro-interventional medical devices in the People’s Republic of China and internationally. It offers NUMEN, a coil embolization system; NUMEN FR, a coil detachment system; NUMEN Silk; Tubridge, a flow-diverting stent; Willis, an intracranial stent graft system; Comaneci, an adjustable temporary coil embolization; and Rebridge, an intracranial visualized stent for use in the treatment of hemorrhagic stroke. The company also provides APOLLO, an intracranial stent a balloon-expandable stent to treat intracranial atherosclerotic disease; Bridge, a rapamycin target eluting vertebral artery stent system; and Diveer, an intracranial balloon catheter to treat cerebral atherosclerosis stenosis.
MicroPort NeuroTech Limited Fundamentals Summary
| 2172 fundamental statistics | |
|---|---|
| Market cap | HK$5.42b |
| Earnings (TTM) | HK$157.31m |
| Revenue (TTM) | HK$719.42m |
34.5x
P/E Ratio7.5x
P/S RatioIs 2172 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2172 income statement (TTM) | |
|---|---|
| Revenue | CN¥665.62m |
| Cost of Revenue | CN¥153.83m |
| Gross Profit | CN¥511.79m |
| Other Expenses | CN¥366.24m |
| Earnings | CN¥145.55m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.25 |
| Gross Margin | 76.89% |
| Net Profit Margin | 21.87% |
| Debt/Equity Ratio | 0% |
How did 2172 perform over the long term?
See historical performance and comparison